Immune responses and clinical outcomes following the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in advanced breast cancer patients receiving targeted therapies: a prospective study

Immune responses and clinical outcomes following the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in advanced breast cancer patients receiving targeted therapies: a prospective study

PurposeMetastatic breast cancer patients are the most prevalent oncology population with advanced disease facing COVID-19 pandemic. Immune responses after mRNA-based vaccination during treatment with CDK4/6 inhibitors or HER2-directed agents remain unclear. We conducted a prospective analysis to elu...

Full description

Bibliographic Details
Main Authors: Fabrizio Nelli, Agnese Fabbri, Andrea Botticelli, Diana Giannarelli, Eleonora Marrucci, Cristina Fiore, Antonella Virtuoso, Julio Rodrigo Giron Berrios, Simone Scagnoli, Simona Pisegna, Alessio Cirillo, Valentina Panichi, Annalisa Massari, Maria Assunta Silvestri, Enzo Maria Ruggeri
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-11-01
Series:Frontiers in Oncology
Subjects:
COVID-19 vaccine
third dose
SARS-CoV-2 breakthrough infections
immune response
breast cancer
CDK4/6 inhibitors
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1280416/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1280416/full

Similar Items